PTN

Across TCGA pan-cancer cohorts, PTN Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PTN data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher PTN Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PTN expression acts as an unfavorable survival marker.

DLBC, LUSC, and LIHC are the cancer types where PTN Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	DFS	Median	II,III,IV	0.022	0.837	<.001	12	view →
LUSC	OS	Median	III,IV	0.112	0.664	.003	12	view →
LIHC	OS	Median	All	0.152	0.688	.017	9	view →
PRAD	DFS	Median	All	0.617	0.886	.011	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	III,IV	0.087	0.647	.013	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PTN–DLBC (DFS)

Open the DLBC breakdown →